ONCOGENEX PHARMACEUTICALS IN's ticker is OGXI and the CUSIP is 68230A106. A total of 27 filers reported holding ONCOGENEX PHARMACEUTICALS IN in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $4,000 | -20.0% | 10,229 | 0.0% | 0.00% | – |
| Q1 2017 | $5,000 | 0.0% | 10,229 | 0.0% | 0.00% | – |
| Q4 2016 | $5,000 | 0.0% | 10,229 | 0.0% | 0.00% | – |
| Q3 2016 | $5,000 | -54.5% | 10,229 | 0.0% | 0.00% | – |
| Q2 2016 | $11,000 | +57.1% | 10,229 | 0.0% | 0.00% | – |
| Q1 2016 | $7,000 | -46.2% | 10,229 | 0.0% | 0.00% | – |
| Q4 2015 | $13,000 | -43.5% | 10,229 | 0.0% | 0.00% | – |
| Q3 2015 | $23,000 | -4.2% | 10,229 | 0.0% | 0.00% | – |
| Q2 2015 | $24,000 | -11.1% | 10,229 | -21.5% | 0.00% | – |
| Q1 2015 | $27,000 | -10.0% | 13,029 | 0.0% | 0.00% | – |
| Q4 2014 | $30,000 | -18.9% | 13,029 | -7.8% | 0.00% | – |
| Q3 2014 | $37,000 | -36.2% | 14,129 | -10.2% | 0.00% | – |
| Q2 2014 | $58,000 | -97.7% | 15,729 | -92.5% | 0.00% | – |
| Q1 2014 | $2,477,000 | -46.2% | 210,720 | -50.7% | 0.00% | – |
| Q4 2013 | $4,603,000 | +138.1% | 427,273 | +104.9% | 0.00% | – |
| Q3 2013 | $1,933,000 | -5.7% | 208,527 | -0.3% | 0.00% | – |
| Q2 2013 | $2,050,000 | – | 209,219 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 396,104 | $400,000 | 0.42% |
| Ancora Advisors LLC | 50,865 | $51,000 | 0.01% |
| EAGLE GLOBAL ADVISORS LLC | 145,710 | $146,000 | 0.00% |
| Acrospire Investment Management LLC | 5,200 | $5,000 | 0.00% |
| A.R.T. Advisors, LLC | 57,954 | $57,000 | 0.00% |
| Renaissance Technologies | 876,100 | $876,000 | 0.00% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 4,600 | $5,000 | 0.00% |
| Cutler Group LLC / CA | 11,048 | $11,000 | 0.00% |
| PANAGORA ASSET MANAGEMENT INC | 133,846 | $134,000 | 0.00% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 46,100 | $46,000 | 0.00% |